[EXAS] Exact Sciences Corporation

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Commercial Physical & Biological Resarch

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 14.17 Change: 0.79 (5.9%)
Ext. hours: Change: 0 (0%)

chart EXAS

Refresh chart

Strongest Trends Summary For EXAS

EXAS is in the medium-term up 36% above S&P in 4 months and up 63% above S&P in 1 year. In the long-term up 110% above S&P in 2 years and up 1374% in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Exact Sciences Corporation, a molecular diagnostics company, focuses on developing diagnostic screening products for the early detection and prevention of colorectal pre-cancer and cancer. The company develops the Cologuard, a non-invasive stool-based DNA colorectal cancer screening test that is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer. Its Cologuard test includes proprietary and patented methods that isolate and analyze the human DNA that are shed into stool every day from the exfoliation of cells that line the colon; and also protein marker to detect blood in the stool, utilizing an antibody-based fecal immunochemical test. The company?s stool-based DNA colorectal cancer screening technology also focuses on the inflammatory bowel disease. It has collaboration, license, and purchase agreement with Genzyme Corporation, as well as with Mayo Clinic for developing tests to detect other gastro-intestinal cancers, primarily esophageal and pancreatic cance

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-42.95% ROE-46.37% ROI-45.3%
Current Ratio17.69 Quick Ratio Long Term Debt/Equity0.01 Debt Ratio0.06
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities290 K Cash From Investing Activities16.76 M Cash From Operating Activities-34.5 M Gross Profit3.02 M
Net Profit-39.07 M Operating Profit-39.37 M Total Assets253.02 M Total Current Assets223.26 M
Total Current Liabilities18.73 M Total Debt4.83 M Total Liabilities28.18 M Total Revenue8.12 M
Technical Data
High 52 week104.72 Low 52 week48.29 Last close96.19 Last change-1.59%
RSI47.27 Average true range4.6 Beta0.78 Volume1.89 M
Simple moving average 20 days-1.23% Simple moving average 50 days2.53% Simple moving average 200 days23.74%
Performance Data
Performance Week4.12% Performance Month4.77% Performance Quart8.63% Performance Half38.58%
Performance Year88.76% Performance Year-to-date52.44% Volatility daily3.09% Volatility weekly6.91%
Volatility monthly14.17% Volatility yearly49.08% Relative Volume250.33% Average Volume1.89 M
New High New Low

News

2019-08-20 17:17:32 | Third in wave of Bay Area biotech IPOs eyes $100M windfall after 26 years in business

2019-08-16 13:10:00 | A Breach of Trust? Here's Why the FDA's Taking Aim at Novartis' AveXis

2019-08-08 13:03:43 | 10 Stocks That Can Profit as Global Turmoil Escalates

2019-08-07 10:05:00 | Genomic Health's Second Quarter Was So Great It Got the Company Acquired

2019-08-05 16:20:50 | Here's Why Genetic Testing Stocks Rose as Much as 25.4% in July

2019-08-02 17:18:00 | GENOMIC HEALTH INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Genomic Health, Inc. - GHDX

2019-08-02 06:00:00 | Exact Sciences to participate in August investor conference

2019-08-01 19:20:48 | Acquisition Boosts Exact Sciences' Role in Cancer Diagnostics

2019-07-31 21:15:06 | Exact Sciences Corp EXAS CFO Jeffrey Thomas Elliott Sold $1 million of Shares

2019-07-31 09:42:03 | Pioneering cancer test maker's execs could grab millions in $3 billion buyout

2019-07-31 08:50:00 | Short Seller Left Goes Long on Invitae With $100 Target

2019-07-31 08:26:43 | A Look At The Fair Value Of Exact Sciences Corporation NASDAQ:EXAS

2019-07-30 17:24:13 | Exact Sciences Corp EXAS Q2 2019 Earnings Call Transcript

2019-07-30 16:55:55 | Why Exact Science Made the $2.8 Billion Deal for Genomic

2019-07-30 07:27:00 | Here's Why Exact Sciences Stock Snapped Right Back Into Place

2019-07-30 06:17:00 | Exact Sciences Is Poised to Test New Highs on the Charts

2019-07-29 20:00:00 | SHAREHOLDER ALERT: WeissLaw LLP Investigates Genomic Health, Inc.

2019-07-29 16:21:17 | What to Know about the Exact Sciences–Genomic Health Deal

2019-07-29 16:11:59 | Merger Fever Runs Hot In Pharma: Viagra, Epipen Sellers Announce Matchup

2019-07-29 15:01:51 | Exact Sciences, Genomic deal will yield greater cancer diagnostic R&D in $20B market

2019-07-29 14:42:22 | SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Genomic Health, Inc. to Exact Sciences Corp. is Fair to Shareholders

2019-07-29 14:37:12 | Exact Sciences Stock Breaks Down After Merger Agreement

2019-07-29 11:43:00 | Why Exact Sciences Is Sinking and Genomic Health Is Rising

2019-07-29 10:48:35 | Madison's Exact Sciences to buy cancer diagnostic company in $2.8B deal

2019-07-29 10:05:43 | Exact Sciences to Buy Genomic Health for About $2.8 Billion

2019-07-29 09:29:17 | Stocks - Mylan, Uber Rise Premarket; Pfizer, Domino’s Fall

2019-07-29 08:25:12 | Exact Sciences EXAS Reports Q2 Loss, Tops Revenue Estimates

2019-07-29 08:07:26 | Exact Sciences Will Acquire Genomic Health In $2.8B Deal

2019-07-29 07:32:11 | UPDATE 2-Diagnostic company Exact Sciences to buy Genomic Health in $2.8 bln deal

2019-07-29 07:24:41 | Exact Sciences to buy Genomic Health for $2.8 billion

2019-07-29 07:23:00 | Exact Sciences to combine with Genomic Health in cash and stock deal valued at $2.8 billion

2019-07-29 07:01:00 | Second-quarter revenue increased 94 percent to $200 million and Cologuard test volume increased 93 percent to 415,000

2019-07-29 07:00:00 | Exact Sciences and Genomic Health to Combine, Creating Leading Global Cancer Diagnostics Company

2019-07-29 05:53:00 | Exact Sciences Reaches Deal to Acquire Genomic Health for $2.8 Billion

2019-07-29 02:37:00 | [video]Exact Sciences in Talks to Buy Genomic Health - Report

2019-07-27 18:52:31 | Exact Sciences in advanced talks to buy Genomic Health for $2.8 billion: Bloomberg

2019-07-23 10:32:02 | Earnings Preview: Exact Sciences EXAS Q2 Earnings Expected to Decline

2019-07-17 06:00:00 | Exact Sciences Designated a Great Place to Work-Certified™ Company in 2019

2019-07-10 11:49:05 | 10 Stocks to Sell for an Economic Slowdown

2019-07-09 06:00:00 | Exact Sciences to host annual meeting, second-quarter 2019 results webcasts and calls

2019-07-08 10:07:00 | Why Exact Sciences Corporation Stock Gained Nearly 14% in June

2019-06-26 16:05:00 | Exact Sciences Advances Fight Against Colorectal Cancer With Opening Of New Laboratory

2019-06-25 15:06:39 | What Kind Of Shareholders Own Exact Sciences Corporation NASDAQ:EXAS?

2019-06-17 17:51:32 | Hedge Funds Have Never Been More Bullish On EXACT Sciences Corporation EXAS

2019-06-15 08:04:36 | See what the IHS Markit Score report has to say about Exact Sciences Corp.

2019-06-04 08:06:59 | See what the IHS Markit Score report has to say about Exact Sciences Corp.

2019-06-04 07:35:59 | Jim Cramer Gives His Opinion On Wendy's, Exelon And More

2019-05-31 06:00:00 | Exact Sciences to participate in June investor conferences

2019-05-28 08:46:12 | The Zacks Analyst Blog Highlights: Guardant, Illumina, Exact Sciences and Pfizer

2019-05-28 08:02:45 | See what the IHS Markit Score report has to say about Exact Sciences Corp.